One significant challenge for current antibody-based cancer therapies that target MUC16-expressing tumors is the fact that the majority of the extracellular domain of MUC16 is cleaved and secreted, limiting the efficacy of MUC16 as a target antigen for ovarian cancer [5, 40]. The gene discussed is MUC16; the disease is ovarian carcinoma.